Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or South Carolina for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to South Carolina only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. South Carolina (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Jill Sullivan (NPI 1174818355)

Field	Value
Entity Type	Individual
Organization	Jill Sullivan
Address	701 Grove Rd
City	Greenville
State	SC
ZIP	29605
Taxonomy	Internal Medicine Physician
NPI Enumerated	June 15, 2011

Payer Source	Total Paid
Medicare	$3.4M
Medicaid	$0

Key Findings

This provider is heavily Medicare-focused and effectively single-payer: lifetime Medicare revenue is $3.4M and there is no Medicaid billing on file. The absence of any Medicaid claims indicates the provider’s billing activity and revenue base are concentrated entirely within Medicare beneficiaries and related services.

Revenue concentration is high: the precomputed top 3 Medicare codes account for 65.2% of the provider’s total Medicare revenue. Those top codes are dominated by high-cost oncology/immunotherapy agents (see J9271, J0897, J9144), indicating that a small set of drug-administering codes generate the majority of billings.

The service mix and business model appear to center on oncology and infusion-based care. J9271 (pembrolizumab) is the single largest revenue driver at $1.3M (41.6% of Medicare revenue), with additional significant revenue from J0897 (denosumab) and J9144 (daratumumab), which together reflect a practice that administers high-volume injectable cancer therapies and supportive agents. The presence of chemotherapy administration code 96413 and multiple infusion/adjunct codes (96367, J1627, J0185) further supports an outpatient infusion or oncology infusion clinic operation.

Competitive standing on several oncology drugs is notable. J9271 ranks #112 of 1841 providers nationally (94th percentile) and is described as "notably above typical national volume," indicating this provider delivers pembrolizumab at volumes well above most peers. J0897 also shows unusually high volume relative to peers (rank #238 of 10057, 98th percentile; "notably above typical national volume"), signaling strong market presence for denosumab injections. Other oncology drug codes (J9144, J9299) are within typical ranges for national volume and do not indicate dominance.

Evaluation-and-management activity appears modest relative to the drug/infusion revenue mix but present at elevated volumes for common office codes. The provider billed 99214 (moderate-complexity established visits) for 843 claims producing $77.6K (2.4% of Medicare revenue) and ranks in the 96th percentile nationally for that code, labeled "notably above typical national volume." Similarly, 99213 shows high national rank (98th percentile) despite lower per-claim revenue, suggesting substantial office-based follow-up or management encounters associated with the infusion practice.

Several ancillary and support services rank highly versus peers, consistent with a high-throughput infusion practice. Routine lab panels (85025, 80048, 80076) and phlebotomy (36415) appear in the top codes with strong national rank percentiles (most in the high 90s), indicating frequent on-site laboratory testing and blood draws that support ongoing infusion care and oncology monitoring. These contribute modestly to revenue but signal integrated point-of-care services.

Tenure is established: the provider’s NPI was enumerated on 2011-06-15 (~15 years ago). That length of enrollment supports a sustained practice presence in the market and helps contextualize the high cumulative Medicare revenue and the developed infusion/oncology service mix.

There are specific statistical outliers in claim volumes: 99213 and 36415 both have very high national ranks (98th and 99th percentiles respectively) and are labeled "extreme outlier" or "typical, unremarkable" as noted, underscoring unusually high visit and phlebotomy volumes relative to most providers. Conversely, several expensive imaging and specialty drug codes (e.g., 78815, 78816, J9304) are within typical or lower percentiles, indicating the practice’s competitive strength is concentrated in certain drug administrations rather than imaging or less-common specialty therapies.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

86 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	30,800	$40	$1.3M
J0897	Injection, denosumab, 1 mg	21,660	$20	$389.9K
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	9,720	$40	$359.6K
J9299	Injection, nivolumab, 1 mg	12,760	$20	$306.2K
J9304	Injection, pemetrexed (pemfexy), 10 mg	2,370	$50	$125.3K
J1449	Injection, eflapegrastim-xnst, 0.1 mg	3,830	$30	$95.7K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	840	$90	$77.6K
J1627	Injection, granisetron, extended-release, 0.1 mg	12,100	$10	$60.5K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	920	$60	$57K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	580	$100	$55.1K

Showing 1–10 of 86

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 86 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. South Carolina Distribution

Jill Sullivan — 7 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — South Carolina

Full comparison — all codes billed, vs. state median

86 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	2	30	19,700	$40	$832K
J9299	12	10	15,760	$20	$432K
J9144	4	10	8,460	$40	$349.4K
J9304	1	10	2,370	$50	$124.8K
J1449	7	10	4,090	$30	$98.8K
J0897	12	250	2,400	$20	$91.2K
J3490	15	50	70	$510	$57.7K
J2506	13	10	740	$80	$55.9K
Q5122	10	10	540	$90	$55.6K
J1627	6	10	10,400	$1	$46.3K

Showing 1–10 of 86

Related Providers

Other providers that share a Tax Identification Number (TIN) with Jill Sullivan, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Charles Butler	SC	Internal Medicine Physician	$3.8M	$0
Robert Collins	SC	Internal Medicine Physician	$2.7M	$0
Woodrow Coker	SC	Hospitalist Physician	$2.6M	$0
South Carolina Oncology Assoc PA	SC	Hematology & Oncology Physician	$0	$2.5M
Scott Sommers	SC	Hematology & Oncology Physician	$2.3M	$0
Mohamed El Geneidy	SC	Hematology & Oncology Physician	$2.1M	$0
Chaudhry Mushtaq	SC	Hematology & Oncology Physician	$2M	$0
Anne Hutchison	SC	Hematology & Oncology Physician	$2M	$0
Steven Minter	SC	Internal Medicine Physician	$1.9M	$0
Fred Kudrik	SC	Hematology & Oncology Physician	$1.7M	$0

Nearby Providers

Other providers in the same ZIP code as Jill Sullivan, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Prisma Health-upstate	SC	General Acute Care Hospital	$0	$86.9M
Prisma Health-upstate	SC	General Acute Care Hospital	$0	$25M
Prisma Health-upstate	SC	General Acute Care Hospital	$0	$22M
Heavenly Care Services Inc.	SC	Nursing Care Agency	$0	$12.1M
Speechworks, Inc.	SC	Speech-Language Pathologist	$0	$10.5M
Plan Home Health Care	SC	Nursing Care Agency	$0	$8.9M
Prisma Health-upstate	SC	General Acute Care Hospital	$0	$8.3M
Prisma Health-upstate	SC	Land Ambulance	$4.5M	$3.7M
Prisma Health-upstate	SC	Infusion Therapy Clinic/Center	$0	$7.5M
Prisma Health University Medical Group	SC	Diagnostic Radiology Physician	$0	$7.5M

Jill Sullivan — Billing Profile & Reimbursement Data

Sign up for Jill Sullivan — Billing Profile & Reimbursement Data policy alerts

Jill Sullivan — Billing Profile & Reimbursement Data

Sign up for Jill Sullivan — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References